Red Door has promoted the product's use for treating rheumatoid arthritis since last year but has now bagged a PR/med-ed contract spanning MabThera's entire repertoire.
It won the brief in a four-way pitch (PRWeek, 11 November 2005).
Ketchum previously promoted MabThera in the non-Hodgkin's lymphoma area. The agency continues to promote the brand internationally.
Roche is seeking European approval for the product to treat what is known as indolent lymphoma.